Search all medical codes

Lutetium lu 177, dotatate, therapeutic, 1 millicurie

HCPCS code

Name of the Procedure:

Common name: Lutetium-177 DOTATATE therapy
Technical/Medical term: Radioisotope therapy with Lutetium-177 DOTATATE (HCPCS code: A9513)


Lutetium-177 DOTATATE therapy is a specialized treatment involving a radioactive substance used to target and treat specific types of tumors, primarily neuroendocrine tumors. This medication helps to shrink tumors and relieve symptoms associated with these cancers.


Medical conditions: Primarily used for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Goals/Outcomes: The procedure aims to reduce tumor size, slow down the progression of the disease, relieve symptoms, and potentially improve patient survival rates.


Specific symptoms/conditions: This therapy is appropriate for patients with advanced neuroendocrine tumors that express somatostatin receptors and have not responded sufficiently to other treatments.
Patient criteria: Candidates typically have confirmed diagnosis through imaging studies, possess well- to moderately-differentiated neuroendocrine tumors, and have a performance status indicating they can tolerate the treatment.


Pre-procedure instructions:

  • Fasting may be required starting a few hours before the procedure.
  • Adjustments to current medications might be recommended; specific instructions will be provided by the healthcare team.
  • Pre-treatment imaging and blood tests to assess general health and specific markers.

Procedure Description

  1. Preparation: The patient arrives at the treatment center.
  2. Administration: Lutetium-177 DOTATATE is administered intravenously over 30-60 minutes.
  3. Monitoring: The patient remains under observation for several hours post-infusion to manage any immediate side effects.

Tools/Equipment: Infusion pump, IV line, and the Lutetium-177 DOTATATE compound.
Anesthesia/Sedation: Typically, no anesthesia or sedation is required.


The infusion of Lutetium-177 DOTATATE itself takes about 30-60 minutes, with additional hours post-infusion for monitoring.


The procedure is usually performed in a hospital or specialized outpatient clinic equipped with the necessary facilities for handling radioactive substances and monitoring patients post-treatment.


A multidisciplinary team includes:

  • Nuclear medicine specialists.
  • Oncologists.
  • Radiologists.
  • Nurses specialized in oncology and nuclear medicine.

Risks and Complications

Common risks: Nausea, vomiting, fatigue, and mild bone marrow suppression.
Rare risks: Severe kidney toxicity, liver toxicity, or blood disorders such as anemia or leukopenia. Management typically involves symptomatic treatment and close monitoring.


Expected benefits: Reduction in tumor size, symptom relief (such as pain or hormone-related symptoms), and improved quality of life. Results may be seen within weeks to a few months post-treatment.


Post-procedure care: Hydration is encouraged to help clear the radioactive substance from the body. Regular follow-up blood tests and imaging studies are required to monitor response and manage any side effects.
Recovery time: Varies by individual, but patients generally resume normal activities within days, with some restrictions, such as avoiding close contact with young children and pregnant women for a few days post-treatment.


Other treatment options: Surgery, traditional chemotherapy, other forms of radiotherapy, targeted therapies, or symptom management with hormonal treatments.
Pros and cons: Alternatives might be less invasive or have fewer immediate side effects but may not be as effective for specific tumor types or advanced stages.

Patient Experience

During the procedure: Most patients tolerate the procedure well but may feel some discomfort at the IV site.
After the procedure: Fatigue and mild nausea are common but are manageable with medications and rest. Patients are often advised to drink plenty of fluids and take it easy for a few days. Pain management protocols will be in place to ensure comfort.

Medical Policies and Guidelines for Lutetium lu 177, dotatate, therapeutic, 1 millicurie

Related policies from health plans

Similar Codes